567 related articles for article (PubMed ID: 30895524)
1. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
2. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
3. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
4. Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.
Kwon HJ; Kim N; Kim HS
Exp Mol Med; 2017 Mar; 49(3):e311. PubMed ID: 28360428
[TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Chiossone L; Vienne M; Kerdiles YM; Vivier E
Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
[TBL] [Abstract][Full Text] [Related]
9. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
10. Improving natural killer cell cancer immunotherapy.
Berrien-Elliott MM; Romee R; Fehniger TA
Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
[TBL] [Abstract][Full Text] [Related]
11. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
Alfarra H; Weir J; Grieve S; Reiman T
Front Immunol; 2020; 11():575609. PubMed ID: 33304346
[TBL] [Abstract][Full Text] [Related]
12. Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.
Yang C; Li Y; Yang Y; Chen Z
J Immunol Res; 2020; 2020():8459496. PubMed ID: 32411806
[TBL] [Abstract][Full Text] [Related]
13. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
14. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
15. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
16. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
17. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
Jiang D; Zhang J; Mao Z; Shi J; Ma P
Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
[TBL] [Abstract][Full Text] [Related]
18. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
19. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
20. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]